Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes.
Alessandro RizzoLucia RinaldiRaffaella MassafraAntonio CusmaiDeniz Can GuvenDaniele La ForgiaAgnese LatorreFrancesco GiottaPublished in: Future oncology (London, England) (2024)
Aim: There is limited data available regarding the comparison of Sacituzumab govitecan (SG) vs. chemotherapy in metastatic breast cancer patients. Materials & methods: We performed a systematic review and meta-analysis aimed to assess the safety profile of SG vs. chemotherapy for metastatic breast cancer (mBC) clinical trials. Results: The pooled odds ratio for outcomes such as grade 3-4 and all grade neutropenia, leukopenia, anemia and other non-hematological adverse events showed a higher risk for patients receiving SG. No statistically significant differences were reported in terms of grade 3-4 fatigue, all grade nausea, febrile neutropenia and treatment discontinuation due to adverse events. Conclusion: Our data, coupled with a statistically and clinically meaningful survival benefit, support the use of SG for mBC.
Keyphrases
- metastatic breast cancer
- chemotherapy induced
- clinical trial
- locally advanced
- electronic health record
- squamous cell carcinoma
- small cell lung cancer
- chronic kidney disease
- type diabetes
- metabolic syndrome
- depressive symptoms
- radiation therapy
- rectal cancer
- adipose tissue
- insulin resistance
- phase iii
- physical activity
- glycemic control
- sleep quality
- clinical evaluation
- phase ii
- weight loss